RxDoctor Payments Data

Harry Dietz, MD

Clinical Genetics (M.D.) · Baltimore, MDNPI 1114954906

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,255,938 of the $1,482,181 with a category attached, or 84.7%. GSK accounts for 96.0% of it on its own, with 1 other manufacturer making up the rest.

$1,482,181in general payments, 2019–2025

Across 31 payments — averaging $47,812 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1.4M
  • Aytu Biopharma, Inc.$60K

What the payments were for

  • Consulting fees$225,81715%
  • Speaking & faculty fees$1,255,93885%
  • Travel & lodging$3180%
  • Food & beverage$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK25$1,422,181
Aytu Biopharma, Inc.6$60,000

How this compares

Too few clinical genetics (m.d.) providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,041
Medicare patients
14
Services billed
14

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical genetics (m.d.) in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →